Research Article

Targeted detection of prostate cancer proteins in serum using heavy-isotope-labeled-peptide standards and MALDI-TOF/TOF

  1. Yan Li1,
  2. Lori J. Sokoll1,
  3. John Rush2,
  4. Danni Meany1,
  5. Nan Zou3,
  6. Daniel W. Chan1,
  7. Hui Zhang Dr.1,*

Article first published online: 22 APR 2009

DOI: 10.1002/prca.200800197

Issue

PROTEOMICS - Clinical Applications

PROTEOMICS - Clinical Applications

Volume 3, Issue 5, pages 597–608, No. 5 May 2009

Additional Information

How to Cite

Li, Y., Sokoll, L. J., Rush, J., Meany, D., Zou, N., Chan, D. W. and Zhang, H. (2009), Targeted detection of prostate cancer proteins in serum using heavy-isotope-labeled-peptide standards and MALDI-TOF/TOF. Prot. Clin. Appl., 3: 597–608. doi: 10.1002/prca.200800197

Author Information

  1. 1

    Department of Pathology, Johns Hopkins University, Baltimore, MD, USA

  2. 2

    Cell Signaling Technology, Danvers, MA, USA

  3. 3

    Univeristy of Maryland, College Park, MD, USA

*Department of Pathology, Johns Hopkins University, 1550 Orleans Street, CRBII, Room 3M-03, Baltimore, MD 21231, USA

Publication History

  1. Issue published online: 22 APR 2009
  2. Article first published online: 22 APR 2009
  3. Manuscript Received: 27 SEP 2008

Funded by

  • National Cancer Institute, National Institutes of Health. Grant Number: R21-CA-114852
  • Early Detection and Research Network (EDRN)
  • Patrick C. Walsh Prostate Cancer Research Fund

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (373K)

Keywords:

  • Glycoprotein;
  • Mass spectrometry;
  • Prostate cancer;
  • Serum

Abstract

Proteins released from cancer tissues to patient sera can potentially be used to achieve sensitive, specific, and early detection of cancer by means of blood tests. In this study, we used a platform that combines glycopeptide capture, heavy-isotope-labeled-peptide standards, and liquid chromatography coupled to tandem mass spectrometry to determine which glycoproteins from prostate cancer can be detected in sera from patients with early-stage prostate cancer. The detection limit for prostate-specific antigen in serum was 3.44 ng/mL; thus, direct identification of low abundance, cancer-specific proteins was achieved using our platform. We showed that prostatic acid phosphatase and membrane metallo-endopeptidase that were detected in sera were preferentially expressed in prostate cancer tissues. Levels of these two proteins were elevated in biopsy-positive patients but not biopsy-negative groups. Therefore, these two proteins are candidate biomarkers for analysis of patient samples with levels of prostate-specific antigen in the diagnostic gray zone.

Get PDF (373K)